Navigation Links
Device effective in zapping the pain out of migraines

An electronic device designed to "zap" away migraine pain before it starts may be the next form of relief for millions of people who suffer from the debilitating disease.

Results of a study found that the experimental device appears to be effective in eliminating the headache when administered during the onset of the migraine.

The study, led by the Ohio State University Medical Center neurology investigators, was presented Thursday (6/22) at the annual American Headache Society meeting in Los Angeles .

A subsequent study will examine the device in a larger population.

The device, called TMS, interrupts the aura phase of the migraine, often described as electrical storms in the brain, before they lead to headaches. Auras are neural disturbances that signal the onset of migraine headaches. People who suffer from migraine headaches often describe "seeing" showers of shooting stars, zigzagging lines and flashing lights, and experiencing loss of vision, weakness, tingling or confusion. What typically follows these initial symptoms is intense throbbing head pain, nausea and vomiting.

Yousef Mohammad, a neurologist at OSU Medical Center who presented the results, says that the patients in this study reported a significant reduction in nausea, noise and light sensitivity post treatment.

"Perhaps the most significant effect of using the TMS device was on the two-hour symptom assessment, with 84 percent of the episodes in patients using the TMS occurring without noise sensitivity. Work functioning also improved, and there were no side effects reported," Mohammad said.

The stimulator sends a strong electric current through a metal coil, which creates an intense magnetic field for about one millisecond. This magnetic pulse, when held against a person's head, creates an electric current in the neurons of the brain, interrupting the aura before it results in a throbbing headache.

"The device's pulses are painl ess. The patients have felt a little pressure, but that's all," said Mohammad, who is principal investigator of the study at Ohio State .

"In our study sample, 69 percent of the TMS-related headaches reported to have either no or mild pain at the two-hour post-treatment point compared to 48 percent of the placebo group. In addition, 42 percent of the TMS-treated patients graded their headache response, without symptoms, as very good or excellent compared to 26 percent for the placebo group. These are very encouraging results."

It was previously believed that migraine headaches start with vascular constriction, which results in an aura, followed by vascular dilation that will lead to a throbbing headache. However, in the late 1990s it was instead suggested that neuronal electrical hyper excitability resulted in a throbbing headache. This new understanding of the migraine mechanism has assisted with the development of the TMS device.


Source:Ohio State University

Related biology news :

1. Implanted Devices Detect High-Risk Heart Failure Patients
2. Team Invents Device For Weighing Individual Molecules
3. Device traps, disables harmful bacteria
4. Combination therapy boosts effectiveness of telomere-directed cancer cell death
5. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
6. Boosting HIV screening can increase survival and is cost effective
7. Live vaccines more effective against horse herpes virus
8. Man-made wetlands effectiveness similar to natural marsh
9. Wake Forest scientists find new combination vaccine effective against plague
10. UCLA study assesses cost-effectiveness of Hepatitis B drugs
11. New study: Sexually transmitted disease treatment can be effectively administered by sex partners
Post Your Comments:

(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: